BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

Genetic alterations in the kinase domain of the epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) patients are associated with sensitivity to treatment with small molecule tyrosine kinase inhibitors. Although first-generation reversible, ATP-competitive inhibitors showed...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Li, D, Ambrogio, L, Shimamura, T, Kubo, S, Takahashi, M, Chirieac, LR, Padera, RF, Shapiro, GI, Baum, A, Himmelsbach, F, Rettig, WJ, Meyerson, M, Solca, F, Greulich, H, Wong, K-K
Formato: Artigo
Idioma:Inglês
Publicado em: 2008
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2748240/
https://ncbi.nlm.nih.gov/pubmed/18408761
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2008.109
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados